↓ Skip to main content

Treating inflammation by blocking interleukin-1 in humans

Overview of attention for article published in Seminars in Immunology, December 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
272 Dimensions

Readers on

mendeley
420 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treating inflammation by blocking interleukin-1 in humans
Published in
Seminars in Immunology, December 2013
DOI 10.1016/j.smim.2013.10.008
Pubmed ID
Authors

Charles A. Dinarello, Jos W.M. van der Meer

Abstract

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1α or IL-1β, was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1α and IL-1β. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 420 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 3 <1%
United Kingdom 3 <1%
United States 3 <1%
Germany 2 <1%
Peru 1 <1%
Brazil 1 <1%
France 1 <1%
Iran, Islamic Republic of 1 <1%
Mexico 1 <1%
Other 1 <1%
Unknown 403 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 85 20%
Student > Master 64 15%
Researcher 59 14%
Student > Bachelor 44 10%
Student > Doctoral Student 30 7%
Other 104 25%
Unknown 34 8%
Readers by discipline Count As %
Medicine and Dentistry 142 34%
Agricultural and Biological Sciences 88 21%
Biochemistry, Genetics and Molecular Biology 43 10%
Immunology and Microbiology 32 8%
Pharmacology, Toxicology and Pharmaceutical Science 12 3%
Other 56 13%
Unknown 47 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2020.
All research outputs
#8,052,766
of 15,647,079 outputs
Outputs from Seminars in Immunology
#418
of 656 outputs
Outputs of similar age
#103,403
of 263,772 outputs
Outputs of similar age from Seminars in Immunology
#10
of 15 outputs
Altmetric has tracked 15,647,079 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 656 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.